Obexelimab clinical trials
Also written XmAb5871.
How each study uses obexelimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2016 | 3 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Zenas BioPharma (USA), LLC (4) · Xencor, Inc. (3)
Studies
Open first, then newest update. How each study uses obexelimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of Obexelimab in Patients With Systemic Lupus ErythematosusActive, not recruitingPhase 2Zenas BioPharma (USA), LLCNCT06559163Written as Obexelimab
- A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseActive, not recruitingPhase 3Zenas BioPharma (USA), LLCNCT05662241Written as Obexelimab
- A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)Active, not recruitingPhase 2Zenas BioPharma (USA), LLCNCT06564311Written as Obexelimab
- A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)Active, not recruitingPhase 3Zenas BioPharma (USA), LLCNCT05786573Written as Obexelimab
- A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus ErythematosusCompletedPhase 2Xencor, Inc.NCT02725515Written as XmAb5871
- Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)CompletedPhase 2Xencor, Inc.NCT02725476Written as XmAb5871
- XmAb5871 Bioavailability StudyCompletedPhase 1Xencor, Inc.NCT02867098Written as XmAb5871
Codes
What other systems call obexelimab · ClinicalTrials.gg INT017806
- UNII (FDA) RM16A4BA8ROBEXELIMABConfirmed FDA, Wikidata
- Wikidata Q123907237obexelimabConfirmed FDA, Wikidata
- NCI Thesaurus C170236ObexelimabOne source FDA
- DrugBank DB15032One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RM16A4BA8R | OBEXELIMAB | Confirmed FDA, Wikidata |
| Wikidata | Q123907237 | obexelimab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C170236 | Obexelimab | One source FDA |
| DrugBank | DB15032 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.